Novartis has reported positive data from a real-world comparison study of its Jakavi (ruxolitinib) drug conducted to treat patients with polycythemia vera (PV), a rare incurable blood cancer.Jakavi is an oral inhibitor of the JAK […]
Axovant Sciences has signed an exclusive worldwide licensing agreement with Oxford BioMedica to develop and commercialise, OXB-10, to treat Parkinson’s disease. Through using LentiVector platform, Oxford BioMedica has developed OXB-102 gene therapy for Parkinson’s […]
A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage […]
Israel-based pharmaceutical company Teva has announced confirmation that the US Food and Drugs Administration (FDA) will make a decision on the company’s migraine treatment fremanezumab by 16 September. The FDA had originally said it […]
Sandoz has secured approval from the European Commission for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn’s […]